*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Study of systemic comorbidities in patients of psoriasis

Author: DR. CHAVHAN, DR. SUGAT JAWADE, A.V.BAPAT
Abstract: Background/rationale: Psoriasis is a chronic immunological inflammatory disease. The etiology of psoriasis is unknown, but it is believed to be multi-factorial with several factors like genetic susceptibility, environmental triggers in combination with skin barrier disruption and immune dysfunction. The disease primarily involves joints and skin, and clinically diagnosed as erythematous plaque covered with silvery scales on extensor surface of body , scalp, umbilicus, and lumbar area. As psoriasis is the most common Th1 cell mediated immunological disease, there is association of other diseases utilising the same pathway which are cardiovascular diseases. Other than these psoriatic patients also show association with metabolic syndrome, liver diseases, renal impairment and malignancies. Therefore, it is very important to identify and treat the co-morbidity associated in psoriatic patients so as to increase their survival and quality of life. Objectives: 1. To study systemic co-morbidities in patients of psoriasis 2. To study systemic co-morbidities in control group/ normal healthy patients3.To study the association between psoriasis and systemic co-morbidities. Methods: It is Observational, Prospective, Case control study and will be carried out on patients of Psoriasis, as well as the patients with non- psoriatic skin diseases with age > 18 years, attending the Out Patient and In Patient Department of Dermatology, AVBRH, will be enrolled after taking into consideration inclusion and exclusion criteria during the period from September 2019 to August 2021. A detailed clinical cutaneous examination will be done and height, weight, BMI and waist circumference of individuals of both the groups will be taken, then both cases and controls will be evaluated for detailed systemic indices which will include Complete blood count with peripheral smear, RFT, LFT, Fasting and Postprandial blood glucose levels and HbA1c, Fasting lipid profile, C-reactive protein, Erythrocyte sedimentation rate, Urine routine and microscopy, Chest x ray ,Hepatic and renal ultrasonography, ECG and Echocardiography . Comparison of all the parameters and results will be done between cases and controls. Expected Results: The result would be undertaken in SPSS software. Conclusion: The conclusion will be based on findings for study of protocol.
Keyword: psoriasis, co-morbidities, cardiovascular, metabolic.
DOI: https://doi.org/10.31838/ijpr/2019.11.01.217
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free